Amarin is one of the names mentioned in the healthcare sector
“AMARIN: Take a chance on me? This could be the most interesting one, as it will be binary (so buckle up). Bottom line: Stock trading down to $12 makes the risk/reward set up into the KEY month-end Patent ruling is VERY interesting (certainly more interesting than it was at $24/share at the end of December). Prior to the sell off, investors were thinking risk-reward in the high single digits on a patent loss vs high $20s/low $30s on a win. If you have conviction that the company is able to effectively defend their patent, this could be a good time to look at the story again.”
Market Data 
Markets 
AI
